The role of cytokines in inflammatory bone loss

References

• Abu-Amer Y. (2001). IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-κB. J Clin Invest, 107, 1375–85
   PubMed Web of Science ®Google Scholar
• Abu-Amer Y, Ross F, Edwards J, Teitelbaum S. (1997). Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor. J Clin Invest, 100, 1557–65
   PubMedGoogle Scholar
• Adamopoulos IE, Chao CC, Geissler R, et al. (2010). Interleukin-17A up-regulates receptor activator of NF-κB on osteoclast precursors. Arthritis Res Ther, 12, R29
   PubMed Web of Science ®Google Scholar
• Adamopoulos IE, Tessmer M, Chao CC, et al. (2011). IL-23 is critical for induction of arthritis, osteoclast formation, and maintenance of bone mass. J Immunol, 187, 951–9
   PubMed Web of Science ®Google Scholar
• Agrawal M, Arora S, Li J, et al. (2011). Bone, inflammation, and inflammatory bowel disease. Curr Osteoporos Rep, 9, 251–7
   Google Scholar
• Aguila H, Mun S, Kalinowski J, et al. (2012). Osteoblast-specific overexpression of human interleukin-7 rescues the bone mass phenotype of interleukin-7-deficient female mice. J Bone Miner Res, 27, 1030–42
   Google Scholar
• Ahlen J, Andersson S, Mukohyama H, et al. (2002). Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bones. Bone, 31, 242–51
   Google Scholar
• Allan E, Hilton D, Brown M, et al. (1990). Osteoblasts display receptors for and responses to leukemia-inhibitory factor. J Cell Physiol, 145, 110–9
   Google Scholar
• Alten R, Gram H, Joosten L, et al. (2008). The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther, 10, R67
   PubMed Web of Science ®Google Scholar
• Arend W, Palmer G, Gabay C. (2008). IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev, 223, 20–38
   PubMed Web of Science ®Google Scholar
• Aya K, Alhawagri M, Hagen-Stapleton A, et al. (2005). NF-(κ)B-inducing kinase controls lymphocyte and osteoclast activities in inflammatory arthritis. J Clin Invest, 115, 1848–54
   PubMed Web of Science ®Google Scholar
• Baker PJ, Dixon M, Evans RT, et al. (1999). CD4(+) T cells and the proinflammatory cytokines gamma interferon and interleukin-6 contribute to alveolar bone loss in mice. Infect Immun, 67, 2804–9
   PubMed Web of Science ®Google Scholar
• Balavoine JF, Derochemonteix B, Williamson K, et al. (1986). Prostaglandin-E2 and Collagenase Production by Fibroblasts and Synovial-Cells Is Regulated by Urine-Derived Human Interleukin-1 and Inhibitor(S). J Clin Invest, 78, 1120–4
   PubMed Web of Science ®Google Scholar
• Banchereau J, Pascual V, O'Garra A. (2012). From IL-2 to IL-37: The expanding spectrum of anti-inflammatory cytokines. Nat Immunol, 13, 925–31
   PubMed Web of Science ®Google Scholar
• Banchereau J, Steinman RM. (1998). Dendritic cells and the control of immunity. Nature, 392, 245–52
   PubMed Web of Science ®Google Scholar
• Barrow AD, Raynal N, Andersen TL, et al. (2011). OSCAR is a collagen receptor that costimulates osteoclastogenesis in DAP12-deficient humans and mice. J Clin Invest, 121, 3505–16
   PubMed Web of Science ®Google Scholar
• Baud'huin M, Renault R, Charrier C, et al. (2010). Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis. J pathol, 221, 77–86
   PubMed Web of Science ®Google Scholar
• Bazan J. (1990). Haemopoietic receptors and helical cytokines. Immunology today, 11, 350–4
   PubMedGoogle Scholar
• Bellido T, Stahl N, Farruggella T, et al. (1996). Detection of receptors for interleukin-6, interleukin-11, leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor in bone marrow stromal/osteoblastic cells. J Clin Invest, 97, 431–7
   PubMed Web of Science ®Google Scholar
• Bendixen AC, Shevde NK, Dienger KM, et al. (2001). IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1. Proc Natl Acad Sci USA, 98, 2443–8
   PubMed Web of Science ®Google Scholar
• Bendre M, Margulies A, Walser B, et al. (2005). Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-κB ligand pathway. Cancer Res, 65, 11001–9
   PubMed Web of Science ®Google Scholar
• Bendre M, Montague D, Peery T, et al. (2003). Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone, 33, 28–37
   PubMed Web of Science ®Google Scholar
• Bertolini D, Nedwin G, Bringman T, et al. (1986). Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature, 319, 516–8
   PubMed Web of Science ®Google Scholar
• Binder N, Puchner A, Niederreiter B, et al. (2013). Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis. Arthritis Rheum, 65, 608–17
   PubMedGoogle Scholar
• Blüml S, Binder N, Niederreiter B, et al. (2010). Antiinflammatory effects of tumor necrosis factor on hematopoietic cells in a murine model of erosive arthritis. Arthritis Rheum, 62, 1608–19
   PubMed Web of Science ®Google Scholar
• Bonar S, Brydges S, Mueller J, et al. (2012). Constitutively activated NLRP3 inflammasome causes inflammation and abnormal skeletal development in mice. PLoS One, 7, e35979
   Google Scholar
• Borden EC, Sen GC, Uze G, et al. (2007). Interferons at age 50: Past, current and future impact on biomedicine. Nat Rev Drug Discov, 6, 975–90
   PubMed Web of Science ®Google Scholar
• Boyce BF. (2013). Advances in osteoclast biology reveal potential new drug targets and new roles for osteoclasts. J Bone Miner Res, 28, 711–22
   PubMed Web of Science ®Google Scholar
• Boyce B, Aufdemorte T, Garrett I, et al. (1989). Effects of interleukin-1 on bone turnover in normal mice. Endocrinology, 125, 1142–50
   PubMed Web of Science ®Google Scholar
• Boyce BF, Yao Z, Xing L. (2010). Functions of nuclear factor κB in bone. Ann N Y Acad Sci, 1192, 367–75
   PubMed Web of Science ®Google Scholar
• Bozec A, Bakiri L, Hoebertz A, et al. (2008). Osteoclast size is controlled by Fra-2 through LIF/LIF-receptor signalling and hypoxia. Nature, 454, 221–5
   PubMed Web of Science ®Google Scholar
• Braun T, Schett G. (2012). Pathways for bone loss in inflammatory disease. Curr Osteoporos Rep, 10, 101–8
   PubMedGoogle Scholar
• Braun T, Zwerina J. (2011). Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis. Arthritis Res Ther, 13, 235
   PubMed Web of Science ®Google Scholar
• Bravo J, Heath JK. (2000). Receptor recognition by gp130 cytokines. EMBO J, 19, 2399–411
   PubMedGoogle Scholar
• Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. (1998). Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum, 41, 2196–204
   PubMed Web of Science ®Google Scholar
• Bucay N, Sarosi I, Dunstan CR, et al. (1998). osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev, 12, 1260–8
   PubMed Web of Science ®Google Scholar
• Burnham JM. (2012). Inflammatory diseases and bone health in children. Curr Opin Rheumatol, 24, 548–53
   Google Scholar
• Cabal-Hierro L, Lazo P. (2012). Signal transduction by tumor necrosis factor receptors. Cellular signalling, 24, 1297–305
   PubMed Web of Science ®Google Scholar
• Cagnard N, Letourneur F, Essabbani A, et al. (2005). Interleukin-32, CCL2, PF4F1 and GFD10 are the only cytokine/chemokine genes differentially expressed by in vitro cultured rheumatoid and osteoarthritis fibroblast-like synoviocytes. European cytokine network, 16, 289–92
   PubMed Web of Science ®Google Scholar
• Cao Y, Doodes P, Glant T, Finnegan A. (2008). IL-27 induces a Th1 immune response and susceptibility to experimental arthritis. J Immunol, 180, 922–30
   PubMed Web of Science ®Google Scholar
• Carriere V, Roussel L, Ortega N, et al. (2007). IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA, 104, 282–7
   PubMed Web of Science ®Google Scholar
• Cayrol C, Girard J-P. (2009). The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci USA, 106, 9021–6
   PubMed Web of Science ®Google Scholar
• Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. (2004). Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med, 10, 858–64
   PubMed Web of Science ®Google Scholar
• Chabaud M, Fossiez F, Taupin JL, Miossec P. (1998). Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol, 161, 409–14
   PubMed Web of Science ®Google Scholar
• Chan AS, Jensen KK, Skokos D, et al. (2009). Id1 represses osteoclast-dependent transcription and affects bone formation and hematopoiesis. PLoS One, 4, e7955
   Google Scholar
• Cheleuitte D, Mizuno S, Glowacki J. (1998). In vitro secretion of cytokines by human bone marrow: Effects of age and estrogen status. J Clin Endocrinol Metab, 83, 2043–51
   PubMedGoogle Scholar
• Chen Z, Buki K, Vaaraniemi J, et al. (2011). The critical role of IL-34 in osteoclastogenesis. PLoS One, 6, e18689
   PubMed Web of Science ®Google Scholar
• Cheng J, Liu J, Shi Z, et al. (2011). Interleukin-4 inhibits RANKL-induced NFATc1 expression via STAT6: A novel mechanism mediating its blockade of osteoclastogenesis. J Cell Biochem, 112, 3385–92
   PubMed Web of Science ®Google Scholar
• Chen L, Wei XQ, Evans B, et al. (2008). IL-23 promotes osteoclast formation by up-regulation of receptor activator of NF-κB (RANK) expression in myeloid precursor cells. Eur J Immunol, 38, 2845–54
   PubMed Web of Science ®Google Scholar
• Chiaramonte MG, Mentink-Kane M, Jacobson BA, et al. (2003). Regulation and function of the interleukin 13 receptor alpha 2 during a T helper cell type 2-dominant immune response. J Exp Med, 197, 687–701
   PubMed Web of Science ®Google Scholar
• Chihara T, Suzu S, Hassan R, et al. (2010). IL-34 and M-CSF share the receptor Fms but are not identical in biological activity and signal activation. Cell Death Differ, 17, 1917–27
   PubMed Web of Science ®Google Scholar
• Cielinski MJ, Marks SC Jr. (1995). Bone metabolism in the osteopetrotic rat mutation microphthalmia blanc. Bone, 16, 567–74
   Google Scholar
• Clohisy JC, Roy BC, Biondo C, et al. (2003). Direct inhibition of NF-κ B blocks bone erosion associated with inflammatory arthritis. J Immunol, 171, 5547–53
   PubMed Web of Science ®Google Scholar
• Clohisy JC, Yamanaka Y, Faccio R, Abu-Amer Y. (2006). Inhibition of IKK activation, through sequestering NEMO, blocks PMMA-induced osteoclastogenesis and calvarial inflammatory osteolysis. J Orthop Res, 24, 1358–65
   PubMed Web of Science ®Google Scholar
• Cobelli N, Scharf B, Crisi GM, et al. (2011). Mediators of the inflammatory response to joint replacement devices. Nat Rev Rheumatol, 7, 600–8
   PubMed Web of Science ®Google Scholar
• Cohen S, Hurd E, Cush J, et al. (2002). Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum, 46, 614–24
   PubMed Web of Science ®Google Scholar
• Conaway HH, Persson E, Halen M, et al. (2009). Retinoids inhibit differentiation of hematopoietic osteoclast progenitors. FASEB J, 23, 3526–38
   Google Scholar
• Cornish J, Callon K, King A, et al. (1993). The effect of leukemia inhibitory factor on bone in vivo. Endocrinology, 132, 1359–66
   PubMed Web of Science ®Google Scholar
• Crockett JC, Mellis DJ, Scott DI, Helfrich MH. (2011). New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: Focus on the RANK/RANKL axis. Osteoporos Int, 22, 1–20
   PubMed Web of Science ®Google Scholar
• Croft M, Duan W, Choi H, et al. (2012). TNF superfamily in inflammatory disease: Translating basic insights. Trends in immunology, 33, 144–52
   PubMed Web of Science ®Google Scholar
• Cundy T, Reid IR. (2012). Paget's disease of bone. Clin Biochem, 45, 43–8
   Google Scholar
• Cush J, Splawski J, Thomas R, et al. (1995). Elevated interleukin-10 levels in patients with rheumatoid arthritis. Arthritis Rheum, 38, 96–104
   PubMed Web of Science ®Google Scholar
• D'Andrea A, Yoshimura A, Youssoufian H, et al. (1991). The cytoplasmic region of the erythropoietin receptor contains nonoverlapping positive and negative growth-regulatory domains. Mol Cell Biol, 11, 1980–7
   PubMed Web of Science ®Google Scholar
• Dai S, Hirayama T, Abbas S, Abu-Amer Y. (2004a). The IκB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. J Biol Chem, 279, 37219–22
   PubMedGoogle Scholar
• Dai SM, Nishioka K, Yudoh K. (2004b). Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: Comparison with IL1 beta and tumour necrosis factor alpha. Ann Rheum Dis, 63, 1379–86
   PubMed Web of Science ®Google Scholar
• Dai XM, Ryan GR, Hapel AJ, et al. (2002). Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood, 99, 111–20
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Massa M, Pignatti P, et al. (1995). Elevated circulating interleukin-7 levels in patients with systemic juvenile rheumatoid arthritis. J Rheumatol, 22, 1581–5
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Rucci N, Del Fattore A, et al. (2006). Impaired skeletal development in interleukin-6-transgenic mice: A model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum, 54, 3551–63
   PubMed Web of Science ®Google Scholar
• Derouet D, Rousseau F, Alfonsi F, et al. (2004). Neuropoietin, a new IL-6-related cytokine signaling through the ciliary neurotrophic factor receptor. Proc Natl Acad Sci USA, 101, 4827–32
   PubMedGoogle Scholar
• DeSelm CJ, Takahata Y, Warren J, et al. (2012). IL-17 mediates estrogen-deficient osteoporosis in an Act1-dependent manner. J Cell Biochem, 113, 2895–902
   PubMedGoogle Scholar
• Dewhirst FE, Stashenko PP, Mole JE, Tsurumachi T. (1985). Purification and partial sequence of human osteoclast-activating factor: Identity with interleukin 1 beta. J Immunol, 135, 2562–8
   PubMed Web of Science ®Google Scholar
• Dhimolea E. (2010). Canakinumab. mAbs, 2, 3-13
   PubMed Web of Science ®Google Scholar
• Dinarello CA. (1994). The interleukin-1 family: 10 years of discovery. FASEB J, 8, 1314–25
   PubMed Web of Science ®Google Scholar
• Dinarello C, Ikejima T, Warner S, et al. (1987). Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. Journal of immunology (Baltimore, Md. : 1950), 139, 1902–10
   PubMed Web of Science ®Google Scholar
• Djaafar S, Pierroz D, Chicheportiche R, et al. (2010). Inhibition of T cell-dependent and RANKL-dependent osteoclastogenic processes associated with high levels of bone mass in interleukin-15 receptor-deficient mice. Arthritis Rheum, 62, 3300–10
   Google Scholar
• Dougall WC, Glaccum M, Charrier K, et al. (1999). RANK is essential for osteoclast and lymph node development. Genes Dev, 13, 2412–24
   PubMed Web of Science ®Google Scholar
• Dubois S, Mariner J, Waldmann T, Tagaya Y. (2002). IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity, 17, 537–47
   PubMed Web of Science ®Google Scholar
• Elson GCA, Lelièvre E, Guillet C, et al. (2000). CLF associates with CLC to form a functional heteromeric ligand for the CNTF receptor complex. Nature neuroscience, 3, 867–72
   PubMed Web of Science ®Google Scholar
• Eskan MA, Jotwani R, Abe T, et al. (2012). The leukocyte integrin antagonist Del-1 inhibits IL-17-mediated inflammatory bone loss. Nat Immunol, 13, 465–73
   PubMed Web of Science ®Google Scholar
• Evans K, Fox S. (2007). Interleukin-10 inhibits osteoclastogenesis by reducing NFATc1 expression and preventing its translocation to the nucleus. BMC cell biology, 8, 4
   PubMed Web of Science ®Google Scholar
• Fan X, Biskobing D, Fan D, et al. (1997). Macrophage colony stimulating factor down-regulates MCSF-receptor expression and entry of progenitors into the osteoclast lineage. J Bone Miner Res, 12, 1387–95
   PubMed Web of Science ®Google Scholar
• Fichtner-Feigl S, Strober W, Kawakami K, et al. (2006). IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med, 12, 99–106
   PubMed Web of Science ®Google Scholar
• Finnegan A, Kaplan C, Cao Y, et al. (2003). Collagen-induced arthritis is exacerbated in IL-10-deficient mice. Arthritis Res Ther, 5, R18–R24
   PubMed Web of Science ®Google Scholar
• Fox SW, Chambers TJ. (2000). Interferon-gamma directly inhibits TRANCE-induced osteoclastogenesis. Biochem Biophys Res Commun, 276, 868–72
   Google Scholar
• Fransson C, Tomasi C, Pikner SS, et al. (2010). Severity and pattern of peri-implantitis-associated bone loss. J Clin Periodontol, 37, 442–8
   PubMed Web of Science ®Google Scholar
• Franzoso G, Carlson L, Xing L, et al. (1997). Requirement for NF-κB in osteoclast and B-cell development. Genes Dev, 11, 3482–96
   PubMed Web of Science ®Google Scholar
• Fujii T, Kitaura H, Kimura K, et al. (2012). IL-4 inhibits TNF-alpha-mediated osteoclast formation by inhibition of RANKL expression in TNF-alpha-activated stromal cells and direct inhibition of TNF-alpha-activated osteoclast precursors via a T-cell-independent mechanism in vivo. Bone, 51, 771–80
   PubMed Web of Science ®Google Scholar
• Fukao T, Matsuda S, Koyasu S. (2000). Synergistic effects of IL-4 and IL-18 on IL-12-dependent IFN-gamma production by dendritic cells. J Immunol, 164, 64–71
   PubMed Web of Science ®Google Scholar
• Furukawa M, Takaishi H, Takito J, et al. (2009). IL-27 abrogates receptor activator of NF-κ B ligand-mediated osteoclastogenesis of human granulocyte-macrophage colony-forming unit cells through STAT1-dependent inhibition of c-Fos. J Immunol, 183, 2397–406
   PubMed Web of Science ®Google Scholar
• Gabay C, McInnes I. (2009). The biological and clinical importance of the ‘new generation' cytokines in rheumatic diseases. Arthritis Res Ther, 11, 230
   Google Scholar
• Gabet Y, Baniwal SK, Leclerc N, et al. (2010). Krox20/EGR2 deficiency accelerates cell growth and differentiation in the monocytic lineage and decreases bone mass. Blood, 116, 3964–71
   Google Scholar
• Gao Y, Grassi F, Ryan MR, et al. (2007). IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest, 117, 122–32
   PubMed Web of Science ®Google Scholar
• Garbers C, Hermanns HM, Schaper F, et al. (2012). Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev, 23, 85–97
   PubMed Web of Science ®Google Scholar
• Garceau V, Smith J, Paton I, et al. (2010). Pivotal Advance: Avian colony-stimulating factor 1 (CSF-1), interleukin-34 (IL-34), and CSF-1 receptor genes and gene products. J Leukoc Biol, 87, 753–64
   PubMed Web of Science ®Google Scholar
• Gearing D, Comeau M, Friend D, et al. (1992). The IL-6 signal transducer, gp130: An oncostatin M receptor and affinity converter for the LIF receptor. Science, 255, 1434–7
   PubMed Web of Science ®Google Scholar
• Gendron S, Boisvert M, Chetoui N, Aoudjit F. (2008). Alpha1beta1 integrin and interleukin-7 receptor up-regulate the expression of RANKL in human T cells and enhance their osteoclastogenic function. Immunology, 125, 359–69
   Google Scholar
• Ghayur T, Banerjee S, Hugunin M, et al. (1997). Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature, 386, 619–23
   PubMed Web of Science ®Google Scholar
• Girasole G, Passeri G, Jilka R, Manolagas S. (1994). Interleukin-11: A new cytokine critical for osteoclast development. J Clin Invest, 93, 1516–24
   PubMed Web of Science ®Google Scholar
• Goldbach-Mansky R, Shroff S, Wilson M, et al. (2008). A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum, 58, 2432–42
   PubMed Web of Science ®Google Scholar
• Goodwin D, Cummins S, Sautkina E, et al. (2013). The role and status of evidence and innovation in the healthy towns programme in England: A qualitative stakeholder interview study. J Epidemiol Community Health, 67, 106–12
   Google Scholar
• Gowen M, Mundy GR. (1986). Actions of recombinant interleukin 1, interleukin 2, and interferon-gamma on bone resorption in vitro. J Immunol, 136, 2478–82
   PubMed Web of Science ®Google Scholar
• Gracie J, Forsey R, Chan W, et al. (1999). A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest, 104, 1393–401
   PubMed Web of Science ®Google Scholar
• Gracie J, Robertson S, McInnes I. (2003). Interleukin-18. J Leukoc Biol, 73, 213–24
   PubMed Web of Science ®Google Scholar
• Grassi F, Cristino S, Toneguzzi S, et al. (2004). CXCL12 chemokine up-regulates bone resorption and MMP-9 release by human osteoclasts: CXCL12 levels are increased in synovial and bone tissue of rheumatoid arthritis patients. J Cell Physiol, 199, 244–51
   PubMed Web of Science ®Google Scholar
• Greenfield E, Gornik S, Horowitz M, et al. (1993). Regulation of cytokine expression in osteoblasts by parathyroid hormone: Rapid stimulation of interleukin-6 and leukemia inhibitory factor mRNA. J Bone Miner Res, 8, 1163–71
   Google Scholar
• Greenfield EM, Shaw SM, Gornik SA, Banks MA. (1995). Adenyl cyclase and interleukin 6 are downstream effectors of parathyroid hormone resulting in stimulation of bone resorption. J Clin Invest, 96, 1238–44
   PubMed Web of Science ®Google Scholar
• Grey A, Mitnick M-A, Masiukiewicz U, et al. (1999). A role for interleukin-6 in parathyroid hormone-induced bone resorption in vivo. Endocrinology, 140, 4683–90
   Google Scholar
• Guerrini MM, Sobacchi C, Cassani B, et al. (2008). Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Am J Hum Genet, 83, 64–76
   PubMed Web of Science ®Google Scholar
• Harrington LE, Hatton RD, Mangan PR, et al. (2005). Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol, 6, 1123–32
   PubMed Web of Science ®Google Scholar
• Hartgring S, Willis C, Alcorn D, et al. (2010). Blockade of the interleukin-7 receptor inhibits collagen-induced arthritis and is associated with reduction of T cell activity and proinflammatory mediators. Arthritis Rheum, 62, 2716–25
   PubMedGoogle Scholar
• Hartgring S, Willis C, Bijlsma J, et al. (2012). Interleukin-7-aggravated joint inflammation and tissue destruction in collagen-induced arthritis is associated with T-cell and B-cell activation. Arthritis Res Ther, 14, R137
   Google Scholar
• Hattersley G, Dorey E, Horton M, Chambers T. (1988). Human macrophage colony-stimulating factor inhibits bone resorption by osteoclasts disaggregated from rat bone. J Cell Physiol, 137, 199–203
   Google Scholar
• Hausmann E, Luderitz O, Knox K, Weinfeld N. (1975). Structural requirements for bone resorption by endotoxin and lipoteichoic acid. J Dent Res 54 Spec No, B, B94–9
   Google Scholar
• Hausmann E, Raisz LG, Miller WA. (1970). Endotoxin: Stimulation of bone resorption in tissue culture. Science, 168, 862–4
   PubMed Web of Science ®Google Scholar
• Hawlisch H, Belkaid Y, Baelder R, et al. (2005). C5a negatively regulates toll-like receptor 4-induced immune responses. Immunity, 22, 415–26
   Web of Science ®Google Scholar
• Hayashi M, Rho M-C, Enomoto A, et al. (2002). Suppression of bone resorption by madindoline A, a novel nonpeptide antagonist to gp130. Proc Natl Acad Sci USA, 99, 14728–33
   Google Scholar
• Heinhuis B, Koenders M, van den Berg W, et al. (2012b). Interleukin 32 (IL-32) contains a typical α-helix bundle structure that resembles focal adhesion targeting region of focal adhesion kinase-1. J Biol Chem, 287, 5733–43
   PubMed Web of Science ®Google Scholar
• Heinhuis B, Netea M, van den Berg W, et al. (2012a). Interleukin-32: A predominantly intracellular proinflammatory mediator that controls cell activation and cell death. Cytokine, 60, 321–7
   PubMed Web of Science ®Google Scholar
• Henningsson L, Jirholt P, Bogestål Y, et al. (2012). Interleukin 15 mediates joint destruction in Staphylococcus aureus arthritis. The Journal of infectious diseases, 206, 687–96
   Google Scholar
• Henriksen K, Bollerslev J, Everts V, Karsdal MA. (2011). Osteoclast activity and subtypes as a function of physiology and pathology–implications for future treatments of osteoporosis. Endocr Rev, 32, 31–63
   PubMed Web of Science ®Google Scholar
• Henschler R, Mantovani L, Oster W, et al. (1990). Interleukin-4 regulates mRNA accumulation of macrophage-colony stimulating factor by fibroblasts: Synergism with interleukin-1 beta. Br J Haematol, 76, 7–11
   PubMed Web of Science ®Google Scholar
• Hodge JM, Collier FM, Pavlos NJ, et al. (2011). M-CSF potently augments RANKL-induced resorption activation in mature human osteoclasts. PLoS One, 6, e21462
   Google Scholar
• Hofbauer L, Lacey D, Dunstan C, et al. (1999). Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone, 25, 255–9
   PubMed Web of Science ®Google Scholar
• Hoffman H, Throne M, Amar N, et al. (2008). Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: Results from two sequential placebo-controlled studies. Arthritis Rheum, 58, 2443–52
   PubMed Web of Science ®Google Scholar
• Hofmann S, Rösen-Wolff A, Tsokos G, Hedrich C. (2012). Biological properties and regulation of IL-10 related cytokines and their contribution to autoimmune disease and tissue injury. Clinical immunology (Orlando, Fla.), 143, 116–27
   PubMed Web of Science ®Google Scholar
• Hong M, Williams H, Jin C, Pike J. (2000). The inhibitory effect of interleukin-10 on mouse osteoclast formation involves novel tyrosine-phosphorylated proteins. J Bone Miner Res, 15, 911–8
   Google Scholar
• Horai R, Saijo S, Tanioka H, et al. (2000). Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med, 191, 313–20
   PubMed Web of Science ®Google Scholar
• Horton JE, Raisz LG, Simmons HA, et al. (1972). Bone resorbing activity in supernatant fluid from cultured human peripheral blood leukocytes. Science, 177, 793–5
   PubMed Web of Science ®Google Scholar
• Horwood N, Elliott J, Martin T, Gillespie M. (1998a). Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology, 139, 4743–6
   PubMedGoogle Scholar
• Horwood N, Elliott J, Martin T, Gillespie M. (2001). IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro. Journal of immunology (Baltimore, Md.: 1950), 166, 4915–21
   PubMed Web of Science ®Google Scholar
• Horwood NJ, Udagawa N, Elliott J, et al. (1998b). Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor. J Clin Invest, 101, 595–603
   PubMed Web of Science ®Google Scholar
• Hsu YH, Chang MS. (2010). Interleukin-20 antibody is a potential therapeutic agent for experimental arthritis. Arthritis Rheum, 62, 3311–21
   PubMed Web of Science ®Google Scholar
• Hsu YH, Chen WY, Chan CH, et al. (2011). Anti-IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss. J Exp Med, 208, 1849–61
   PubMed Web of Science ®Google Scholar
• Hsu YH, Li HH, Hsieh MY, et al. (2006). Function of interleukin-20 as a proinflammatory molecule in rheumatoid and experimental arthritis. Arthritis Rheum, 54, 2722–33
   PubMed Web of Science ®Google Scholar
• Hu R, Sharma SM, Bronisz A, et al. (2007). Eos, MITF, and PU.1 recruit corepressors to osteoclast-specific genes in committed myeloid progenitors. Mol Cell Biol, 27, 4018–27
   PubMed Web of Science ®Google Scholar
• Hu Y, Xiong H, Peng B. (2013). Expression of a cytokine, interleukin-23, in experimental periapical lesions. Int Endod J (Epub ahead of print)
   Google Scholar
• Hume DA, MacDonald KP. (2012). Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood, 119, 1810–20
   PubMed Web of Science ®Google Scholar
• Hunter C, Kastelein R. (2012). Interleukin-27: Balancing protective and pathological immunity. Immunity, 37, 960–9
   PubMed Web of Science ®Google Scholar
• Hwang SJ, Choi B, Kang SS, et al. (2012). Interleukin-34 produced by human fibroblast-like synovial cells in rheumatoid arthritis supports osteoclastogenesis. Arthritis Res Ther, 14, R14
   PubMed Web of Science ®Google Scholar
• Ichihara M, Hara T, Kim H, et al. (1997). Oncostatin M and leukemia inhibitory factor do not use the same functional receptor in mice. Blood, 90, 165–73
   PubMed Web of Science ®Google Scholar
• Ikeuchi H, Kuroiwa T, Hiramatsu N, et al. (2005). Expression of interleukin-22 in rheumatoid arthritis: Potential role as a proinflammatory cytokine. Arthritis Rheum, 52, 1037–46
   PubMed Web of Science ®Google Scholar
• Iotsova V, Caamano J, Loy J, et al. (1997). Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat Med, 3, 1285–9
   PubMed Web of Science ®Google Scholar
• Ishii M, Egen JG, Klauschen F, et al. (2009). Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature, 458, 524–8
   PubMed Web of Science ®Google Scholar
• Ishii M, Kikuta J, Shimazu Y, et al. (2010). Chemorepulsion by blood S1P regulates osteoclast precursor mobilization and bone remodeling in vivo. J Exp Med, 207, 2793–8
   PubMed Web of Science ®Google Scholar
• Ishimi Y, Miyaura C, Jin CH, et al. (1990). IL-6 is produced by osteoblasts and induces bone resorption. J Immunol, 145, 3297–303
   PubMed Web of Science ®Google Scholar
• Iwakura Y, Ishigame H, Saijo S, Nakae S. (2011). Functional specialization of interleukin-17 family members. Immunity, 34, 149–62
   PubMed Web of Science ®Google Scholar
• Jazayeri JA, Carroll GJ, Vernallis AB. (2010). Interleukin-6 subfamily cytokines and rheumatoid arthritis: Role of antagonists. Int Immunopharmacol, 10, 1–8
   Google Scholar
• Ji JD, Park-Min KH, Shen Z, et al. (2009). Inhibition of RANK expression and osteoclastogenesis by TLRs and IFN-gamma in human osteoclast precursors. J Immunol, 183, 7223–33
   PubMed Web of Science ®Google Scholar
• Jilka RL, Hamilton JW. (1984). Inhibition of parathormone-stimulated bone resorption by type I interferon. Biochem Biophys Res Commun, 120, 553–8
   Google Scholar
• Jilka RL, Hangoc G, Girasole G, et al. (1992). Increased osteoclast development after estrogen loss: Mediation by interleukin-6. Science, 257, 88–91
   PubMed Web of Science ®Google Scholar
• Jimi E, Shuto T, Koga T. (1995). Macrophage colony-stimulating factor and interleukin-1 alpha maintain the survival of osteoclast-like cells. Endocrinology, 136, 808–11
   PubMed Web of Science ®Google Scholar
• Johansson AC, Hansson A, Nandakumar K, et al. (2001). IL-10-deficient B10.Q mice develop more severe collagen-induced arthritis, but are protected from arthritis induced with anti-type II collagen antibodies. J Immunol, 167, 3505–12
   PubMed Web of Science ®Google Scholar
• Jones G, Sebba A, Gu J, et al. (2010). Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis, 69, 88–96
   PubMed Web of Science ®Google Scholar
• Joosten L, Heinhuis B, Netea M, Dinarello C. (2013). Novel insights into the biology of interleukin-32. CMLS
   Google Scholar
• Joosten LA, Helsen MM, van de Loo FA, van den Berg WB. (1996). Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum, 39, 797–809
   PubMed Web of Science ®Google Scholar
• Joosten L, Netea M, Kim S-H, et al. (2006). IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci USA, 103, 3298–303
   PubMed Web of Science ®Google Scholar
• Joosten L, van De Loo F, Lubberts E, et al. (2000). An IFN-gamma-independent proinflammatory role of IL-18 in murine streptococcal cell wall arthritis. J Immunol, 165, 6553–8
   PubMed Web of Science ®Google Scholar
• Ju JH, Cho ML, Moon YM, et al. (2008). IL-23 induces receptor activator of NF-κB ligand expression on CD4+ T cells and promotes osteoclastogenesis in an autoimmune arthritis model. J Immunol, 181, 1507–18
   PubMed Web of Science ®Google Scholar
• Jules J, Zhang P, Ashley J, et al. (2012). Molecular basis of requirement of receptor activator of nuclear factor κB signaling for interleukin 1-mediated osteoclastogenesis. J Biol Chem, 287, 15728–38
   Google Scholar
• Kalliolias G, Zhao B, Triantafyllopoulou A, et al. (2010). Interleukin-27 inhibits human osteoclastogenesis by abrogating RANKL-mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signaling. Arthritis Rheum, 62, 402–13
   PubMed Web of Science ®Google Scholar
• Kamel Mohamed SG, Sugiyama E, Shinoda K, et al. (2005). Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: A possible mechanism for down-regulation of osteoclastogenesis. Biochem Biophys Res Commun, 329, 839–45
   PubMed Web of Science ®Google Scholar
• Kamiya S, Nakamura C, Fukawa T, et al. (2007). Effects of IL-23 and IL-27 on osteoblasts and osteoclasts: Inhibitory effects on osteoclast differentiation. J Bone Miner Metab, 25, 277–85
   PubMed Web of Science ®Google Scholar
• Kamiya S, Okumura M, Chiba Y, et al. (2011). IL-27 suppresses RANKL expression in CD4+ T cells in part through STAT3. Immunol Lett, 138, 47–53
   PubMed Web of Science ®Google Scholar
• Kamolmatyakul S, Chen W, Li YP. (2001). Interferon-gamma down-regulates gene expression of cathepsin K in osteoclasts and inhibits osteoclast formation. J Dent Res, 80, 351–5
   Google Scholar
• Kasono K, Sato K, Sato Y, et al. (1993). Inhibitory effect of interleukin-4 on osteoclast-like cell formation in mouse bone marrow culture. Bone Miner, 21, 179–88
   Google Scholar
• Kato Z, Jee J, Shikano H, et al. (2003). The structure and binding mode of interleukin-18. Nature structural biology, 10, 966–71
   PubMedGoogle Scholar
• Kawase Y, Hoshino T, Yokota K, et al. (2003). Bone malformations in interleukin-18 transgenic mice. J Bone Miner Res, 18, 975–83
   PubMed Web of Science ®Google Scholar
• Keffer J, Probert L, Cazlaris H, et al. (1991). Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis. The EMBO journal, 10, 4025–31
   PubMed Web of Science ®Google Scholar
• Keller J, Catala-Lehnen P, Wintges K, et al. (2012). Transgenic over-expression of interleukin-33 in osteoblasts results in decreased osteoclastogenesis. Biochem Biophys Res Commun, 417, 217–22
   Google Scholar
• Key LL, Jr Rodriguiz RM, Willi SM, et al. (1995). Long-term treatment of osteopetrosis with recombinant human interferon gamma. N Engl J Med, 332, 1594–9
   PubMed Web of Science ®Google Scholar
• Kikuta J, Ishii M. (2013). Osteoclast migration, differentiation and function: Novel therapeutic targets for rheumatic diseases. Rheumatology (Oxford), 52, 226–34
   PubMed Web of Science ®Google Scholar
• Kikuta J, Iwai K, Saeki Y, Ishii M. (2011). S1P-targeted therapy for elderly rheumatoid arthritis patients with osteoporosis. Rheumatol Int, 31, 967–9
   Google Scholar
• Kim K, Kim JH, Lee J, et al. (2007). MafB negatively regulates RANKL-mediated osteoclast differentiation. Blood, 109, 3253–9
   PubMed Web of Science ®Google Scholar
• Kim KW, Kim HR, Park JY, et al. (2012). Interleukin-22 promotes osteoclastogenesis in rheumatoid arthritis through induction of RANKL in human synovial fibroblasts. Arthritis Rheum, 64, 1015–23
   PubMed Web of Science ®Google Scholar
• Kim YG, Lee CK, Oh J, et al. (2010). Effect of interleukin-32gamma on differentiation of osteoclasts from CD14+ monocytes. Arthritis Rheum, 62, 515–23
   PubMed Web of Science ®Google Scholar
• Kimble R, Vannice J, Bloedow D, et al. (1994). Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats. J Clin Invest, 93, 1959–67
   PubMed Web of Science ®Google Scholar
• Kitami S, Tanaka H, Kawato T, et al. (2010). IL-17A suppresses the expression of bone resorption-related proteinases and osteoclast differentiation via IL-17RA or IL-17RC receptors in RAW264.7 cells. Biochimie, 92, 398–404
   Google Scholar
• Kitamura H, Kawata H, Takahashi F, et al. (1995). Bone marrow neutrophilia and suppressed bone turnover in human interleukin-6 transgenic mice. A cellular relationship among hematopoietic cells, osteoblasts, and osteoclasts mediated by stromal cells in bone marrow. Am J Pathol, 147, 1682–92
   Google Scholar
• Kitaura H, Nagata N, Fujimura Y, et al. (2002). Effect of IL-12 on TNF-alpha-mediated osteoclast formation in bone marrow cells: Apoptosis mediated by Fas/Fas ligand interaction. J Immunol, 169, 4732–8
   PubMed Web of Science ®Google Scholar
• Kitaura H, Tatamiya M, Nagata N, et al. (2006). IL-18 induces apoptosis of adherent bone marrow cells in TNF-alpha mediated osteoclast formation in synergy with IL-12. Immunol Lett, 107, 22–31
   Google Scholar
• Kitaura H, Zhou P, Kim HJ, et al. (2005). M-CSF mediates TNF-induced inflammatory osteolysis. J Clin Invest, 115, 3418–27
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Fitz L, Ryan M, et al. (1989). Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med, 170, 827–45
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Takahashi N, Jimi E, et al. (2000). Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med, 191, 275–86
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Yamamoto K, Saido T, et al. (1990). Identification of calcium-activated neutral protease as a processing enzyme of human interleukin 1 alpha. Proc Natl Acad Sci USA, 87, 5548–52
   PubMed Web of Science ®Google Scholar
• Koga T, Inui M, Inoue K, et al. (2004). Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature, 428, 758–63
   PubMed Web of Science ®Google Scholar
• Kohara H, Kitaura H, Fujimura Y, et al. (2011). IFN-gamma directly inhibits TNF-alpha-induced osteoclastogenesis in vitro and in vivo and induces apoptosis mediated by Fas/Fas ligand interactions. Immunol Lett, 137, 53–61
   PubMedGoogle Scholar
• Kong YY, Yoshida H, Sarosi I, et al. (1999). OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature, 397, 315–23
   PubMed Web of Science ®Google Scholar
• Kotake S, Sato K, Kim KJ, et al. (1996). Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res, 11, 88–95
   PubMed Web of Science ®Google Scholar
• Kotake S, Udagawa N, Takahashi N, et al. (1999). IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest, 103, 1345–52
   PubMed Web of Science ®Google Scholar
• Kotenko SV. (2011). IFN-lambdas. Curr Opin Immunol, 23, 583–90
   Google Scholar
• Kudo O, Sabokbar A, Pocock A, et al. (2003). Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone, 32, 1–7
   PubMed Web of Science ®Google Scholar
• Kuestner RE, Taft DW, Haran A, et al. (2007). Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F. Journal of Immunology, 179, 5462–73
   PubMed Web of Science ®Google Scholar
• Kumar P, Rajasekaran K, Palmer J, et al. (2013). IL-22: An Evolutionary Missing-Link Authenticating the Role of the Immune System in Tissue Regeneration. Journal of Cancer, 4, 57–65
   Google Scholar
• Kurihara N, Roodman GD. (1990). Interferons-alpha and -gamma inhibit interleukin-1 beta-stimulated osteoclast-like cell formation in long-term human marrow cultures. J Interferon Res, 10, 541–7
   Google Scholar
• Kwok SK, Cho ML, Park MK, et al. (2012). Interleukin-21 promotes osteoclastogenesis in humans with rheumatoid arthritis and in mice with collagen-induced arthritis. Arthritis Rheum, 64, 740–51
   PubMed Web of Science ®Google Scholar
• Lacey DL, Erdmann JM, Teitelbaum SL, et al. (1995). Interleukin 4, interferon-gamma, and prostaglandin E impact the osteoclastic cell-forming potential of murine bone marrow macrophages. Endocrinology, 136, 2367–76
   PubMed Web of Science ®Google Scholar
• Lang D, Knop J, Wesche H, et al. (1998). The type II IL-1 receptor interacts with the IL-1 receptor accessory protein: A novel mechanism of regulation of IL-1 responsiveness. J Immunol, 161, 6871–7
   Google Scholar
• Langrish CL, Chen Y, Blumenschein WM, et al. (2005). IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med, 201, 233–40
   PubMed Web of Science ®Google Scholar
• Lauwerys BR, Renauld JC, Houssiau FA. (1999). Synergistic proliferation and activation of natural killer cells by interleukin 12 and interleukin 18. Cytokine, 11, 822–30
   Google Scholar
• Lee JH, Cho ML, Kim JI, et al. (2009). Interleukin 17 (IL-17) increases the expression of Toll-like receptor-2, 4, and 9 by increasing IL-1beta and IL-6 production in autoimmune arthritis. J Rheumatol, 36, 684–92
   Google Scholar
• Lee B, Kim TH, Jun JB, et al. (2010). Direct inhibition of human RANK+ osteoclast precursors identifies a homeostatic function of IL-1beta. J Immunol, 185, 5926–34
   PubMed Web of Science ®Google Scholar
• Lee SK, Kalinowski J, Jacquin C, et al. (2006). Interleukin-7 influences osteoclast function in vivo but is not a critical factor in ovariectomy-induced bone loss. J Bone Miner Res, 21, 695–702
   Google Scholar
• Lee SK, Kalinowski J, Jastrzebski S, et al. (2003). Interleukin-7 is a direct inhibitor of in vitro osteoclastogenesis. Endocrinology, 144, 3524–31
   PubMed Web of Science ®Google Scholar
• Lee J, Kim K, Kim JH, et al. (2006). Id helix-loop-helix proteins negatively regulate TRANCE-mediated osteoclast differentiation. Blood, 107, 2686–93
   Google Scholar
• Lee J, Lee J, Park MK, et al. (2013). Interferon Gamma Suppresses Collagen-Induced Arthritis by Regulation of Th17 through the Induction of Indoleamine-2,3-Deoxygenase. PLoS One, 8, e60900
   Google Scholar
• Lerner UH, Ohlin A. (1993). Tumor necrosis factors alpha and beta can stimulate bone resorption in cultured mouse calvariae by a prostaglandin-independent mechanism. J Bone Miner Res, 8, 147–55
   PubMed Web of Science ®Google Scholar
• Leung B, McInnes I, Esfandiari E, et al. (2000). Combined effects of IL-12 and IL-18 on the induction of collagen-induced arthritis. J Immunol, 164, 6495–502
   PubMed Web of Science ®Google Scholar
• Li J, Sarosi I, Yan XQ, et al. (2000). RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA, 97, 1566–71
   PubMed Web of Science ®Google Scholar
• Li X, Kim KW, Cho ML, et al. (2010). IL-23 induces receptor activator of NF-κB ligand expression in fibroblast-like synoviocytes via STAT3 and NF-κB signal pathways. Immunol Lett, 127, 100–7
   PubMed Web of Science ®Google Scholar
• Li Y, Messina C, Bendaoud M, et al. (2010). Adaptive immune response in osteoclastic bone resorption induced by orally administered Aggregatibacter actinomycetemcomitans in a rat model of periodontal disease. Molecular oral microbiology, 25, 275–92
   PubMedGoogle Scholar
• Liang S, Krauss JL, Domon H, et al. (2011). The C5a receptor impairs IL-12-dependent clearance of Porphyromonas gingivalis and is required for induction of periodontal bone loss. J Immunol, 186, 869-77
   PubMed Web of Science ®Google Scholar
• Lin H, Lee E, Hestir K, et al. (2008). Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science, 320, 807–11
   PubMed Web of Science ®Google Scholar
• Liu YC, Lerner UH, Teng YT. (2010). Cytokine responses against periodontal infection: Protective and destructive roles. Periodontol (2000), 52, 163–206
   PubMed Web of Science ®Google Scholar
• Lorenzo J, Sousa S, Alander C, et al. (1987). Comparison of the bone-resorbing activity in the supernatants from phytohemagglutinin-stimulated human peripheral blood mononuclear cells with that of cytokines through the use of an antiserum to interleukin 1. Endocrinology, 121, 1164–70
   PubMed Web of Science ®Google Scholar
• Lorenzo J, Sousa S, Leahy C. (1990). Leukemia inhibitory factor (LIF) inhibits basal bone resorption in fetal rat long bone cultures. Cytokine, 2, 266–71
   Google Scholar
• Lubbers J, Brink M, van de Stadt LA, et al. (2013). The type I IFN signature as a biomarker of preclinical rheumatoid arthritis. Ann Rheum Dis, 72, 776–80
   PubMed Web of Science ®Google Scholar
• Lubberts E, Joosten LA, Chabaud M, et al. (2000). IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest, 105, 1697–710
   PubMed Web of Science ®Google Scholar
• Ma T, Miyanishi K, Suen A, et al. (2004). Human interleukin-1-induced murine osteoclastogenesis is dependent on RANKL, but independent of TNF-alpha. Cytokine, 26, 138–44
   PubMed Web of Science ®Google Scholar
• Mabilleau G, Sabokbar A. (2009). Interleukin-32 promotes osteoclast differentiation but not osteoclast activation. PLoS One, 4, e4173
   Google Scholar
• Maini RN, Taylor PC, Szechinski J, et al. (2006). Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum, 54, 2817–29
   PubMed Web of Science ®Google Scholar
• Malinowsky D, Lundkvist J, Layé S, Bartfai T. (1998). Interleukin-1 receptor accessory protein interacts with the type II interleukin-1 receptor. FEBS Lett, 429, 299–302
   Google Scholar
• Mangashetti LS, Khapli SM, Wani MR. (2005). IL-4 inhibits bone-resorbing activity of mature osteoclasts by affecting NF-κB and Ca2+ signaling. J Immunol, 175, 917–25
   PubMedGoogle Scholar
• Mann GN, Jacobs TW, Buchinsky FJ, et al. (1994). Interferon-gamma causes loss of bone volume in vivo and fails to ameliorate cyclosporin A-induced osteopenia. Endocrinology, 135, 1077–83
   Google Scholar
• Martin TJ, Seeman E. (2008). Bone remodelling: Its local regulation and the emergence of bone fragility. Best Pract Res Clin Endocrinol Metab, 22, 701–22
   PubMed Web of Science ®Google Scholar
• Micallef MJ, Ohtsuki T, Kohno K, et al. (1996). Interferon-gamma-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: Synergism with interleukin-12 for interferon-gamma production. Eur J Immunol, 26, 1647–51
   PubMed Web of Science ®Google Scholar
• Miller A. (2011). Role of IL-33 in inflammation and disease. J Inflammation, 8, 22
   Google Scholar
• Miossec P, Chomarat P, Dechanet J, et al. (1994). Interleukin-4 inhibits bone resorption through an effect on osteoclasts and proinflammatory cytokines in an ex vivo model of bone resorption in rheumatoid arthritis. Arthritis Rheum, 37, 1715–22
   PubMedGoogle Scholar
• Miranda-Carús M-E, Benito-Miguel M, Balsa A, et al. (2006). Peripheral blood T lymphocytes from patients with early rheumatoid arthritis express RANKL and interleukin-15 on the cell surface and promote osteoclastogenesis in autologous monocytes. Arthritis Rheum, 54, 1151–64
   Google Scholar
• Miura M, Zhu H, Rotello R, et al. (1993). Induction of apoptosis in fibroblasts by IL-1 beta-converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-3. Cell, 75, 653–60
   PubMed Web of Science ®Google Scholar
• Miyauchi Y, Ninomiya K, Miyamoto H, et al. (2010). The Blimp1-Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis. J Exp Med, 207, 751–62
   PubMed Web of Science ®Google Scholar
• Miyaura C, Onoe Y, Inada M, et al. (1997). Increased B-lymphopoiesis by interleukin 7 induces bone loss in mice with intact ovarian function: Similarity to estrogen deficiency. Proc Natl Acad Sci USA, 94, 9360–5
   PubMed Web of Science ®Google Scholar
• Mócsai A, Humphrey M, Van Ziffle J, et al. (2004). The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc Natl Acad Sci USA, 101, 6158–63
   PubMed Web of Science ®Google Scholar
• Mohamed S, Sugiyama E, Shinoda K, et al. (2007). Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells. Bone, 41, 592–602
   Google Scholar
• Monroe KM, McWhirter SM, Vance RE. (2010). Induction of type I interferons by bacteria. Cell Microbiol, 12, 881–90
   PubMed Web of Science ®Google Scholar
• Moon YM, Yoon BY, Her YM, et al. (2012). IL-32 and IL-17 interact and have the potential to aggravate osteoclastogenesis in rheumatoid arthritis. Arthritis Res Ther, 14, R246
   PubMed Web of Science ®Google Scholar
• Moreno JL, Kaczmarek M, Keegan AD, Tondravi M. (2003). IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism: Irreversible inhibition of the differentiation program activated by RANKL. Blood, 102, 1078–86
   PubMed Web of Science ®Google Scholar
• Morita Y, Kitaura H, Yoshimatsu M, et al. (2010). IL-18 inhibits TNF-alpha-induced osteoclastogenesis possibly via a T cell-independent mechanism in synergy with IL-12 in vivo. Calcif Tissue Int, 86, 242–8
   PubMed Web of Science ®Google Scholar
• Müller J, Waldmann T, Kruhlak M, Dubois S. (2012). Paracrine and transpresentation functions of IL-15 are mediated by diverse splice versions of IL-15Rα in human monocytes and dendritic cells. J Biol Chem, 287, 40328–38
   Google Scholar
• Munder M, Mallo M, Eichmann K, Modolell M. (1998). Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: A novel pathway of autocrine macrophage activation. J Exp Med, 187, 2103–8
   PubMed Web of Science ®Google Scholar
• Murugaiyan G, Saha B. (2013). IL-27 in tumor immunity and immunotherapy. Trends in molecular medicine, 19, 108–16
   Google Scholar
• Nagasaki K, Yamaguchi K, Watanabe K, et al. (1991). Interleukin-4 blocks parathyroid hormone-related protein-induced hypercalcemia in vivo. Biochem Biophys Res Commun, 178, 694–8
   Google Scholar
• Nagata N, Kitaura H, Yoshida N, Nakayama K. (2003). Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: Involvement of IFN-gamma possibly induced from non-T cell population. Bone, 33, 721–32
   Google Scholar
• Nakamichi Y, Mizoguchi T, Arai A, et al. (2012). Spleen serves as a reservoir of osteoclast precursors through vitamin D-induced IL-34 expression in osteopetrotic op/op mice. Proc Natl Acad Sci USA, 109, 10006–11
   PubMed Web of Science ®Google Scholar
• Nakano Y, Watanabe K, Morimoto I, et al. (1994). Interleukin-4 inhibits spontaneous and parathyroid hormone-related protein-stimulated osteoclast formation in mice. J Bone Miner Res, 9, 1533–9
   PubMed Web of Science ®Google Scholar
• Nakashima T, Hayashi M, Takayanagi H. (2012). New insights into osteoclastogenic signaling mechanisms. Trends Endocrinol Metab, 23, 582–90
   PubMed Web of Science ®Google Scholar
• Negishi-Koga T, Takayanagi H. (2009). Ca2+-NFATc1 signaling is an essential axis of osteoclast differentiation. Immunol Rev, 231, 241–56
   PubMed Web of Science ®Google Scholar
• Netea M, Nold-Petry C, Nold M, et al. (2009). Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood, 113, 2324–35
   PubMed Web of Science ®Google Scholar
• Niedbala W, Cai B, Wei X, et al. (2008). Interleukin 27 attenuates collagen-induced arthritis. Ann Rheum Dis, 67, 1474–9
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Hashimoto J, Miyasaka N, et al. (2007). Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis, 66, 1162–7
   PubMed Web of Science ®Google Scholar
• Novack DV. (2011). Role of NF-κB in the skeleton. Cell Res, 21, 169–82
   PubMed Web of Science ®Google Scholar
• Novack DV, Yin L, Hagen-Stapleton A, et al. (2003). The IκB function of NF-κB2 p100 controls stimulated osteoclastogenesis. J Exp Med, 198, 771–81
   PubMedGoogle Scholar
• Novick D, Kim S, Fantuzzi G, et al. (1999). Interleukin-18 binding protein: A novel modulator of the Th1 cytokine response. Immunity, 10, 127–36
   PubMed Web of Science ®Google Scholar
• Nuki G, Bresnihan B, Bear MB, McCabe D. (2002). Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum, 46, 2838–46
   PubMed Web of Science ®Google Scholar
• O'Brien C, Gubrij I, Lin S, et al. (1999). STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-κB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone. J Biol Chem, 274, (1930)1–8
   Google Scholar
• Ogata Y, Kukita A, Kukita T, et al. (1999). A novel role of IL-15 in the development of osteoclasts: Inability to replace its activity with IL-2. J Immunol, 162, 2754–60
   PubMed Web of Science ®Google Scholar
• Ohteki T, Fukao T, Suzue K, et al. (1999). Interleukin 12-dependent interferon gamma production by CD8alpha+ lymphoid dendritic cells. J Exp Med, 189, 1981–6
   PubMed Web of Science ®Google Scholar
• Okamura H, Tsutsi H, Komatsu T, et al. (1995). Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature, 378, 88–91
   PubMed Web of Science ®Google Scholar
• Oppmann B, Lesley R, Blom B, et al. (2000). Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity, 13, 715–25
   PubMed Web of Science ®Google Scholar
• O'Shea J, Gadina M, Schreiber R. (2002). Cytokine signaling in (2002): New surprises in the Jak/Stat pathway. Cell, 109, 31
   Google Scholar
• Otero JE, Chen T, Zhang K, Abu-Amer Y. (2012a). Constitutively active canonical NF-κB pathway induces severe bone loss in mice. PLoS One, 7, e38694
   Google Scholar
• Otero JE, Dai S, Alhawagri MA, et al. (2010). IKKbeta activation is sufficient for RANK-independent osteoclast differentiation and osteolysis. J Bone Miner Res, 25, 1282–94
   PubMed Web of Science ®Google Scholar
• Otero JE, Dai S, Foglia D, et al. (2008). Defective osteoclastogenesis by IKKbeta-null precursors is a result of receptor activator of NF-κB ligand (RANKL)-induced JNK-dependent apoptosis and impaired differentiation. J Biol Chem, 283, 24546–53
   PubMedGoogle Scholar
• Otero K, Shinohara M, Zhao H, et al. (2012b). TREM2 and β-catenin regulate bone homeostasis by controlling the rate of osteoclastogenesis. J Immunol, 188, 2612–21
   PubMed Web of Science ®Google Scholar
• Owens J, Gallagher A, Chambers T. (1996). IL-10 modulates formation of osteoclasts in murine hemopoietic cultures. J Immunol, 157, 936–40
   PubMedGoogle Scholar
• Palmer G, Talabot-Ayer D, Lamacchia C, et al. (2009). Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum, 60, 738–49
   PubMed Web of Science ®Google Scholar
• Palmqvist P, Lundberg P, Persson E, et al. (2006). Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway. J Biol Chem, 281, 2414–29
   PubMed Web of Science ®Google Scholar
• Palmqvist P, Persson E, Conaway HH, Lerner UH. (2002). IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-κB ligand, osteoprotegerin, and receptor activator of NF-κB in mouse calvariae. J Immunol, 169, 3353–62
   PubMed Web of Science ®Google Scholar
• Parham C, Chirica M, Timans J, et al. (2002). A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol, 168, 5699–708
   PubMed Web of Science ®Google Scholar
• Park H, Li Z, Yang XO, et al. (2005). A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol, 6, 1133–41
   PubMed Web of Science ®Google Scholar
• Park JS, Jung Y, Oh HJ, et al. (2012). Interleukin-27 suppresses osteoclastogenesis via induction of interferon-γ. Immunology, 137, 326–35
   Google Scholar
• Park M, Her YM, Cho M, et al. (2011). IL-15 promotes osteoclastogenesis via the PLD pathway in rheumatoid arthritis. Immunol Lett, 139, 42–51
   PubMed Web of Science ®Google Scholar
• Park YD, Kim YS, Jung YM, et al. (2012). Porphyromonas gingivalis lipopolysaccharide regulates interleukin (IL)-17 and IL-23 expression via SIRT1 modulation in human periodontal ligament cells. Cytokine, 60, 284–93
   PubMed Web of Science ®Google Scholar
• Park-Min KH, Ji JD, Antoniv T, et al. (2009). IL-10 suppresses calcium-mediated costimulation of receptor activator NF-κB signaling during human osteoclast differentiation by inhibiting TREM-2 expression. J Immunol, 183, 2444–55
   Google Scholar
• Park-Min KH, Lee EY, Moskowitz NK, et al. (2013). Negative regulation of osteoclast precursor differentiation by CD11b and beta2 integrin-B-cell lymphoma 6 signaling. J Bone Miner Res, 28, 135–49
   Google Scholar
• Perkins SL, Kling SJ. (1995). Local concentrations of macrophage colony-stimulating factor mediate osteoclastic differentiation. Am J Physiol, 269, E1024–30
   Google Scholar
• Persson S, Mikulowska A, Narula S, et al. (1996). Interleukin-10 suppresses the development of collagen type II-induced arthritis and ameliorates sustained arthritis in rats. Scandinavian journal of immunology, 44, 607–14
   Google Scholar
• Pestka S, Krause CD, Walter MR. (2004). Interferons, interferon-like cytokines, and their receptors. Immunol Rev, 202, 8–32
   PubMed Web of Science ®Google Scholar
• Peterlik M, Hoffmann O, Swetly P, et al. (1985). Recombinant gamma-interferon inhibits prostaglandin-mediated and parathyroid hormone-induced bone resorption in cultured neonatal mouse calvaria. FEBS Lett, 185, 287–90
   Google Scholar
• Pickens S, Chamberlain N, Volin M, et al. (2011b). Local expression of interleukin-27 ameliorates collagen-induced arthritis. Arthritis Rheum, 63, 2289–98
   Google Scholar
• Pickens S, Chamberlain N, Volin M, et al. (2011a). Characterization of interleukin-7 and interleukin-7 receptor in the pathogenesis of rheumatoid arthritis. Arthritis Rheum, 63, 2884–93
   PubMedGoogle Scholar
• Platanias LC. (2005). Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol, 5, 375–86
   PubMed Web of Science ®Google Scholar
• Poli V, Balena R, Fattori E, et al. (1994). Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. The EMBO journal, 13, 1189–96
   PubMed Web of Science ®Google Scholar
• Popadiak K, Potempa J, Riesbeck K, Blom AM. (2007). Biphasic effect of gingipains from Porphyromonas gingivalis on the human complement system. J Immunol, 178, 7242–50
   Web of Science ®Google Scholar
• Presky D, Yang H, Minetti L, et al. (1996). A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc Natl Acad Sci USA, 93, 14002–7
   PubMed Web of Science ®Google Scholar
• Puddu P, Fantuzzi L, Borghi P, et al. (1997). IL-12 induces IFN-gamma expression and secretion in mouse peritoneal macrophages. J Immunol, 159, 3490–7
   PubMed Web of Science ®Google Scholar
• Qian Y, Liu C, Hartupee J, et al. (2007). The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease. Nat Immunol, 8, 247–56
   PubMed Web of Science ®Google Scholar
• Quinn JM, Sims NA, Saleh H, et al. (2008). IL-23 inhibits osteoclastogenesis indirectly through lymphocytes and is required for the maintenance of bone mass in mice. J Immunol, 181, 5720–9
   PubMed Web of Science ®Google Scholar
• Ratner M. (2008). IL-1 trap go-ahead. Nature biotechnology, 26, 485
   PubMedGoogle Scholar
• Redlich K, Smolen J. (2012). Inflammatory bone loss: Pathogenesis and therapeutic intervention. Nat Rev Drug Discov, 11, 234–50
   PubMed Web of Science ®Google Scholar
• Reid L, Lowe C, Cornish J, et al. (1990). Leukemia inhibitory factor: A novel bone-active cytokine. Endocrinology, 126, 1416–20
   PubMed Web of Science ®Google Scholar
• Riancho JA, Zarrabeitia MT, Gonzalez-Macias J. (1993b). Interleukin-4 modulates osteoclast differentiation and inhibits the formation of resorption pits in mouse osteoclast cultures. Biochem Biophys Res Commun, 196, 678–85
   PubMedGoogle Scholar
• Riancho JA, Zarrabeitia MT, Mundy GR, et al. (1993a). Effects of interleukin-4 on the formation of macrophages and osteoclast-like cells. J Bone Miner Res, 8, 1337–44
   Google Scholar
• Richards C, Langdon C, Deschamps P, et al. (2000). Stimulation of osteoclast differentiation in vitro by mouse oncostatin M, leukaemia inhibitory factor, cardiotrophin-1 and interleukin 6: synergy with dexamethasone. Cytokine, 12, 613–21
   Google Scholar
• Romas E, Udagawa N, Zhou H, et al. (1996). The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures. J Exp Med, 183, 2581–91
   PubMedGoogle Scholar
• Ruchatz H, Leung B, Wei X, et al. (1998). Soluble IL-15 receptor alpha-chain administration prevents murine collagen-induced arthritis: A role for IL-15 in development of antigen-induced immunopathology. J Immunol, 160, 5654–60
   PubMed Web of Science ®Google Scholar
• Ruocco MG, Maeda S, Park JM, et al. (2005). IκB kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med, 201, 1677–87
   PubMed Web of Science ®Google Scholar
• Ruth J, Park C, Amin M, et al. (2010). Interleukin-18 as an in vivo mediator of monocyte recruitment in rodent models of rheumatoid arthritis. Arthritis Res Ther, 12, R118
   PubMedGoogle Scholar
• Ryan M, Shepherd R, Leavey J, et al. (2005). An IL-7-dependent rebound in thymic T cell output contributes to the bone loss induced by estrogen deficiency. Proc Natl Acad Sci USA, 102, 16735–40
   Google Scholar
• Sabatini M, Boyce B, Aufdemorte T, et al. (1988). Infusions of recombinant human interleukins 1 alpha and 1 beta cause hypercalcemia in normal mice. Proc Natl Acad Sci USA, 85, 5235–9
   PubMed Web of Science ®Google Scholar
• Saleh H, Eeles D, Hodge J, et al. (2011). Interleukin-33, a target of parathyroid hormone and oncostatin m, increases osteoblastic matrix mineral deposition and inhibits osteoclast formation in vitro. Endocrinology, 152, 1911–22
   PubMed Web of Science ®Google Scholar
• Sarra M, Cupi M, Pallone F, Monteleone G. (2012). Interleukin-21 in immune and allergic diseases. Inflammation & allergy drug targets, 11, 313–9
   Google Scholar
• Sasaki H, Okamatsu Y, Kawai T, et al. (2004). The interleukin-10 knockout mouse is highly susceptible to Porphyromonas gingivalis-induced alveolar bone loss. Journal of periodontal research, 39, 432–41
   PubMed Web of Science ®Google Scholar
• Sato K, Fujii Y, Kasono K, et al. (1986). Stimulation of prostaglandin E2 and bone resorption by recombinant human interleukin 1 alpha in fetal mouse bones. Biochem Biophys Res Commun, 138, 618–24
   PubMed Web of Science ®Google Scholar
• Sato K, Suematsu A, Okamoto K, et al. (2006). Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med, 203, 2673–82
   PubMed Web of Science ®Google Scholar
• Schett G, Gravallese E. (2012). Bone erosion in rheumatoid arthritis: Mechanisms, diagnosis and treatment. Nat Rev Rheumatol, 8, 656–64
   PubMed Web of Science ®Google Scholar
• Schmitz J, Owyang A, Oldham E, et al. (2005). IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity, 23, 479–90
   PubMed Web of Science ®Google Scholar
• Schroder K, Tschopp J. (2010). The inflammasomes. Cell, 140, 821–32
   PubMed Web of Science ®Google Scholar
• Schulze J, Bickert T, Beil F, et al. (2011). Interleukin-33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells. J Bone Miner Res, 26, 704–17
   PubMed Web of Science ®Google Scholar
• Seckinger P, Williamson K, Balavoine J, et al. (1987). A urine inhibitor of interleukin 1 activity affects both interleukin 1 alpha and 1 beta but not tumor necrosis factor alpha. J Immunol, 139, 1541–5
   PubMed Web of Science ®Google Scholar
• Seder RA, Paul WE. (1994). Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu Rev Immunol, 12, 635–73
   PubMed Web of Science ®Google Scholar
• Shalom-Barak T, Quach J, Lotz M. (1998). Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-κB. J Biol Chem, 273, 27467–73
   PubMed Web of Science ®Google Scholar
• Shanmugarajan S, Kawanabe N, Koide M, et al. (2009). IL-12 stimulates the osteoclast inhibitory peptide-1 (OIP-1/hSca) gene expression in CD4+ T cells. J Cell Biochem, 107, 104–11
   Google Scholar
• Shen F, Ruddy MJ, Plamondon P, Gaffen SL. (2005). Cytokines link osteoblasts and inflammation: Microarray analysis of interleukin-17- and TNF-alpha-induced genes in bone cells. J Leukoc Biol, 77, 388–99
   PubMed Web of Science ®Google Scholar
• Shioi A, Teitelbaum SL, Ross FP, et al. (1991). Interleukin 4 inhibits murine osteoclast formation in vitro. J Cell Biochem, 47, 272–7
   PubMed Web of Science ®Google Scholar
• Silva MJ, Kajiya M, AlShwaimi E, et al. (2012). Bacteria-reactive immune response may induce RANKL-expressing T cells in the mouse periapical bone loss lesion. J Endod, 38, 346–50
   Google Scholar
• Simonet WS, Lacey DL, Dunstan CR, et al. (1997). Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell, 89, 309–19
   PubMed Web of Science ®Google Scholar
• Sims N. (2009). gp130 signaling in bone cell biology: Multiple roles revealed by analysis of genetically altered mice. Molecular and cellular endocrinology, 310, 30–9
   Google Scholar
• Sims NA, Jenkins BJ, Nakamura A, et al. (2005). Interleukin-11 receptor signaling is required for normal bone remodeling. J Bone Miner Res, 20, 1093–102
   PubMed Web of Science ®Google Scholar
• Sims N, Walker E, Poulton I, et al. (2007). Oncostatin M is an essential stimulus of bone formation and osteoclastogenesis. J. Bone Miner Res, 22, S19
   Google Scholar
• Smeets TJ, Dayer JM, Kraan MC, et al. (2000). The effects of interferon-beta treatment of synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis. Arthritis Rheum, 43, 270–4
   PubMed Web of Science ®Google Scholar
• Smith D. (2011). The biological paths of IL-1 family members IL-18 and IL-33. J Leukoc Biol, 89, 383–92
   PubMed Web of Science ®Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A, et al. (2008). Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial. Lancet, 371, 987–97
   PubMed Web of Science ®Google Scholar
• Sobacchi C, Frattini A, Guerrini MM, et al. (2007). Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet, 39, 960–2
   PubMed Web of Science ®Google Scholar
• Souza PP, Palmqvist P, Lundberg P, et al. (2012). Interleukin-4 and interleukin-13 inhibit the expression of leukemia inhibitory factor and interleukin-11 in fibroblasts. Mol Immunol, 49, 601–10
   Google Scholar
• Souza PPC, Brechter AB, Reis RI, et al. (2013). IL-4 and IL-13 inhibit IL-1β and TNF-α induced kinin B1 and B2 receptors through a STAT6-dependent mechanism. Br J Pharmacol, 169, 400–12
   PubMed Web of Science ®Google Scholar
• Stashenko P, Dewhirst F, Peros W, et al. (1987). Synergistic interactions between interleukin 1, tumor necrosis factor, and lymphotoxin in bone resorption. J Immunol, 138, 1464–8
   PubMed Web of Science ®Google Scholar
• Stashenko P, Goncalves RB, Lipkin B, et al. (2007). Th1 immune response promotes severe bone resorption caused by Porphyromonas gingivalis. Am J Pathol, 170, 203–13
   Google Scholar
• Steel J, Waldmann T, Morris J. (2012). Interleukin-15 biology and its therapeutic implications in cancer. Trends in pharmacological sciences, 33, 35–41
   PubMed Web of Science ®Google Scholar
• Stein NC, Kreutzmann C, Zimmermann SP, et al. (2008). Interleukin-4 and interleukin-13 stimulate the osteoclast inhibitor osteoprotegerin by human endothelial cells through the STAT6 pathway. J Bone Miner Res, 23, 750–8
   PubMed Web of Science ®Google Scholar
• Stoll S, Jonuleit H, Schmitt E, et al. (1998). Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development. Eur J Immunol, 28, 3231–9
   PubMed Web of Science ®Google Scholar
• Stoll S, Müller G, Kurimoto M, et al. (1997). Production of IL-18 (IFN-gamma-inducing factor) messenger RNA and functional protein by murine keratinocytes. J Immunol, 159, 298–302
   PubMed Web of Science ®Google Scholar
• Taga T, Hibi M, Hirata Y, et al. (1989). Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell, 58, 573–81
   PubMed Web of Science ®Google Scholar
• Tak PP, Hart BA, Kraan MC, et al. (1999). The effects of interferon beta treatment on arthritis. Rheumatology (Oxford), 38, 362–9
   PubMed Web of Science ®Google Scholar
• Takahashi N, Mundy GR, Roodman GD. (1986). Recombinant human interferon-gamma inhibits formation of human osteoclast-like cells. J Immunol, 137, 3544–9
   PubMed Web of Science ®Google Scholar
• Takayanagi H. (2012). New developments in osteoimmunology. Nat Rev Rheumatol, 8, 684–9
   PubMed Web of Science ®Google Scholar
• Takayanagi H, Iizuka H, Juji T, et al. (2000a). Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum, 43, 259–69
   PubMed Web of Science ®Google Scholar
• Takayanagi H, Kim S, Koga T, et al. (2002a). Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell, 3, 889–901
   PubMed Web of Science ®Google Scholar
• Takayanagi H, Kim S, Matsuo K, et al. (2002b). RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature, 416, 744–9
   PubMed Web of Science ®Google Scholar
• Takayanagi H, Kim S, Taniguchi T. (2002c). Signaling crosstalk between RANKL and interferons in osteoclast differentiation. Arthritis Res 4 Suppl, 3, S227–32
   Google Scholar
• Takayanagi H, Ogasawara K, Hida S, et al. (2000b). T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature, 408, 600–5
   PubMed Web of Science ®Google Scholar
• Takeshita S, Namba N, Zhao JJ, et al. (2002). SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts. Nat Med, 8, 943–9
   PubMed Web of Science ®Google Scholar
• Tamura T, Udagawa N, Takahashi N, et al. (1993). Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA, 90, 11924–8
   PubMed Web of Science ®Google Scholar
• Tashjian A, Voelkel E, Lazzaro M, et al. (1987). Tumor necrosis factor-alpha (cachectin) stimulates bone resorption in mouse calvaria via a prostaglandin-mediated mechanism. Endocrinology, 120, 2029–36
   PubMed Web of Science ®Google Scholar
• Thomson B, Mundy G, Chambers T. (1987). Tumor necrosis factors alpha and beta induce osteoblastic cells to stimulate osteoclastic bone resorption. J Immunol, 138, 775–9
   PubMed Web of Science ®Google Scholar
• Thunell D, Tymkiw K, Johnson G, et al. (2010). A multiplex immunoassay demonstrates reductions in gingival crevicular fluid cytokines following initial periodontal therapy. J Periodontal Res, 45, 148–52
   PubMed Web of Science ®Google Scholar
• Tokuda H, Kanno Y, Ishisaki A, et al. (2004). Interleukin (IL)-17 enhances tumor necrosis factor-alpha-stimulated IL-6 synthesis via p38 mitogen-activated protein kinase in osteoblasts. J Cell Biochem, 91, 1053–61
   PubMed Web of Science ®Google Scholar
• Toraldo G, Roggia C, Qian W-P, et al. (2003). IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor κB ligand and tumor necrosis factor alpha from T cells. Proc Natl Acad Sci USA, 100, 125–30
   PubMed Web of Science ®Google Scholar
• Townsend MJ, Fallon PG, Matthews DJ, et al. (2000). T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J Exp Med, 191, 1069–76
   PubMed Web of Science ®Google Scholar
• Treschow AP, Teige I, Nandakumar KS, et al. (2005). Stromal cells and osteoclasts are responsible for exacerbated collagen-induced arthritis in interferon-beta-deficient mice. Arthritis Rheum, 52, 3739–48
   Google Scholar
• Triantaphyllopoulos KA, Williams RO, Tailor H, Chernajovsky Y. (1999). Amelioration of collagen-induced arthritis and suppression of interferon-gamma, interleukin-12, and tumor necrosis factor alpha production by interferon-beta gene therapy. Arthritis Rheum, 42, 90–9
   PubMed Web of Science ®Google Scholar
• Trinchieri G. (2003). Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol, 3, 133–46
   PubMed Web of Science ®Google Scholar
• Trinchieri G. (2010). Type I interferon: Friend or foe? J Exp Med, 207, 2053–63
   PubMed Web of Science ®Google Scholar
• Tsukii K, Shima N, Mochizuki S, et al. (1998). Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone. Biochem Biophys Res Commun, 246, 337–41
   PubMed Web of Science ®Google Scholar
• Tymkiw K, Thunell D, Johnson G, et al. (2011). Influence of smoking on gingival crevicular fluid cytokines in severe chronic periodontitis. J Clinical Periodontol, 38, 219–28
   PubMed Web of Science ®Google Scholar
• Udagawa N, Horwood NJ, Elliott J, et al. (1997). Interleukin-18 (interferon-gamma-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation. J Exp Med, 185, 1005–12
   PubMed Web of Science ®Google Scholar
• Udagawa N, Takahashi N, Katagiri T, et al. (1995). Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. J Exp Med, 182, 1461–8
   PubMed Web of Science ®Google Scholar
• Vaira S, Alhawagri M, Anwisye I, et al. (2008b). RelA/p65 promotes osteoclast differentiation by blocking a RANKL-induced apoptotic JNK pathway in mice. J Clin Invest, 118, 2088–97
   PubMedGoogle Scholar
• Vaira S, Johnson T, Hirbe AC, et al. (2008a). RelB is the NF-κB subunit downstream of NIK responsible for osteoclast differentiation. Proc Natl Acad Sci USA, 105, 3897–902
   Google Scholar
• Van bezooijen RL, Farih-Sips HC, Papapoulos SE, Lowik CW. (1999). Interleukin-17: A new bone acting cytokine in vitro. J Bone Miner Res, 14, 1513–21
   PubMed Web of Science ®Google Scholar
• Van Bezooijen RL, Papapoulos SE, Lowik CW. (2001). Effect of interleukin-17 on nitric oxide production and osteoclastic bone resorption: Is there dependency on nuclear factor-κB and receptor activator of nuclear factor κB (RANK)/RANK ligand signaling? Bone, 28, 378–86
   PubMed Web of Science ®Google Scholar
• Van Bezooijen RL, Van Der Wee-Pals L, Papapoulos SE, Lowik CW. (2002). Interleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitro. Ann Rheum Dis, 61, 870–6
   PubMed Web of Science ®Google Scholar
• van Roon J, Hartgring S, Wenting-van Wijk M, et al. (2007). Persistence of interleukin 7 activity and levels on tumour necrosis factor alpha blockade in patients with rheumatoid arthritis. Ann Rheum Dis, 66, 664–9
   PubMedGoogle Scholar
• van Roon J, Lafeber F. (2008). Role of interleukin-7 in degenerative and inflammatory joint diseases. Arthritis Res Ther, 10, 107
   PubMedGoogle Scholar
• van't Hof RJ, Ralston SH. (1997). Cytokine-induced nitric oxide inhibits bone resorption by inducing apoptosis of osteoclast progenitors and suppressing osteoclast activity. J Bone Miner Res, 12, 1797–804
   PubMed Web of Science ®Google Scholar
• Volin M, Koch A. (2011). Interleukin-18: A mediator of inflammation and angiogenesis in rheumatoid arthritis. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 31, 745–51
   PubMed Web of Science ®Google Scholar
• Wada N, Maeda H, Yoshimine Y, Akamine A. (2004). Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-κB ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha. Bone, 35, 629–35
   PubMed Web of Science ®Google Scholar
• Wagner EF, Eferl R. (2005). Fos/AP-1 proteins in bone and the immune system. Immunol Rev, 208, 126–40
   PubMed Web of Science ®Google Scholar
• Waldmann T. (2006). The biology of interleukin-2 and interleukin-15: Implications for cancer therapy and vaccine design. Nat Rev Immunol, 6, 595–601
   PubMed Web of Science ®Google Scholar
• Walker E, McGregor N, Poulton I, et al. (2008). Cardiotrophin-1 is an osteoclast-derived stimulus of bone formation required for normal bone remodeling. J Bone Miner Res, 23, 2025–32
   Google Scholar
• Wang Y, Robledo O, Kinzie E, et al. (2000). Receptor subunit-specific action of oncostatin M in hepatic cells and its modulation by leukemia inhibitory factor. J Biol Chem, 275, 25273–85
   PubMed Web of Science ®Google Scholar
• Ware C, Horowitz M, Renshaw B, et al. (1995). Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death. Development, 121, 1283–99
   PubMed Web of Science ®Google Scholar
• Watanabe K, Tanaka Y, Morimoto I, et al. (1990). Interleukin-4 as a potent inhibitor of bone resorption. Biochem Biophys Res Commun, 172, 1035–41
   PubMed Web of Science ®Google Scholar
• Weber A, Wasiliew P, Kracht M. (2010). Interleukin-1 (IL-1) pathway. Sci Signal, 3, 1–2
   Google Scholar
• Wei S, Kitaura H, Zhou P, et al. (2005). IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest, 115, 282–90
   PubMed Web of Science ®Google Scholar
• Wei S, Nandi S, Chitu V, et al. (2010). Functional overlap but differential expression of CSF-1 and IL-34 in their CSF-1 receptor-mediated regulation of myeloid cells. J Leukoc Biol, 88, 495–505
   PubMed Web of Science ®Google Scholar
• Wei S, Wang MW, Teitelbaum SL, Ross FP. (2002). Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-κB and mitogen-activated protein kinase signaling. J Biol Chem, 277, 6622–30
   Google Scholar
• Wei X, Leung B, Arthur H, et al. (2001). Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18. J Immunol, 166, 517–21
   PubMed Web of Science ®Google Scholar
• Weitzmann M, Cenci S, Rifas L, et al. (2000). Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines. Blood, 96, 1873–8
   PubMed Web of Science ®Google Scholar
• Weitzmann M, Roggia C, Toraldo G, et al. (2002). Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency. J Clin Invest, 110, 1643–50
   PubMed Web of Science ®Google Scholar
• Wright JF, Bennett F, Li BL, et al. (2008). The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex. J Immunol, 181, 2799–805
   PubMed Web of Science ®Google Scholar
• Wright LM, Maloney W, Yu X, et al. (2005). Stromal cell-derived factor-1 binding to its chemokine receptor CXCR4 on precursor cells promotes the chemotactic recruitment, development and survival of human osteoclasts. Bone, 36, 840–53
   PubMed Web of Science ®Google Scholar
• Xing L, Bushnell TP, Carlson L, et al. (2002). NF-κB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. J Bone Miner Res, 17, 1200–10
   PubMed Web of Science ®Google Scholar
• Xu S, Cao X. (2010). Interleukin-17 and its expanding biological functions. Cell Mol Immunol, 7, 164–74
   PubMed Web of Science ®Google Scholar
• Xu D, Jiang H-R, Kewin P, et al. (2008). IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci USA, 105, 10913–8
   PubMed Web of Science ®Google Scholar
• Xu L, Kukita T, Kukita A, et al. (1995). Interleukin-10 selectively inhibits osteoclastogenesis by inhibiting differentiation of osteoclast progenitors into preosteoclast-like cells in rat bone marrow culture system. J Cell Physiol, 165, 624–9
   Google Scholar
• Xu Z, Hurchla MA, Deng H, et al. (2009). Interferon-gamma targets cancer cells and osteoclasts to prevent tumor-associated bone loss and bone metastases. J Biol Chem, 284, 4658–66
   PubMedGoogle Scholar
• Yago T, Nanke Y, Ichikawa N, et al. (2009). IL-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-TNF-alpha antibody: A novel mechanism of osteoclastogenesis by IL-17. J Cell Biochem, 108, 947–55
   PubMed Web of Science ®Google Scholar
• Yamada N, Niwa S, Tsujimura T, et al. (2002). Interleukin-18 and interleukin-12 synergistically inhibit osteoclastic bone-resorbing activity. Bone, 30, 901–8
   PubMed Web of Science ®Google Scholar
• Yamanaka Y, Abu-Amer W, Foglia D, et al. (2008). NFAT2 is an essential mediator of orthopedic particle-induced osteoclastogenesis. J Orthop Res, 26, 1577–84
   Google Scholar
• Yamashita T, Yao Z, Li F, et al. (2007). NF-κB p50 and p52 regulate receptor activator of NF-κB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J Biol Chem, 282, 18245–53
   PubMed Web of Science ®Google Scholar
• Yang C, McCoy K, Davis JL, et al (2010). NIK stabilization in osteoclasts results in osteoporosis and enhanced inflammatory osteolysis. PLoS One, 5, e15383
   Google Scholar
• Yang S, Madyastha P, Ries W, Key LL. (2002). Characterization of interferon gamma receptors on osteoclasts: Effect of interferon gamma on osteoclastic superoxide generation. J Cell Biochem, 84, 645–54
   Google Scholar
• Yao Z, Xing L, Boyce BF. (2009). NF-κB p100 limits TNF-induced bone resorption in mice by a TRAF3-dependent mechanism. J Clin Invest, 119, 3024–34
   Google Scholar
• Ying F, Chalise JP, Narendra SC, Magnusson M. (2011). Type I IFN protects against antigen-induced arthritis. Eur J Immunol, 41, 1687-95
   Google Scholar
• Yoshida H, Hayashi S, Kunisada T, et al. (1990). The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature, 345, 442–4
   PubMed Web of Science ®Google Scholar
• Yoshimatsu M, Kitaura H, Fujimura Y, et al. (2009). IL-12 inhibits TNF-alpha induced osteoclastogenesis via a T cell-independent mechanism in vivo. Bone, 45, 1010–6
   PubMed Web of Science ®Google Scholar
• Yoshimatsu M, Kitaura H, Fujimura Y, et al. (2012). Inhibitory effects of IL-12 on experimental tooth movement and root resorption in mice. Arch Oral Biol, 57, 36–43
   PubMed Web of Science ®Google Scholar
• Yoshitake F, Itoh S, Narita H, et al. (2008). Interleukin-6 directly inhibits osteoclast differentiation by suppressing receptor activator of NF-κB signaling pathways. J Biol Chem, 283, 11535–40
   PubMed Web of Science ®Google Scholar
• Yu X, Huang Y, Collin-Osdoby P, Osdoby P. (2003). Stromal cell-derived factor-1 (SDF-1) recruits osteoclast precursors by inducing chemotaxis, matrix metalloproteinase-9 (MMP-9) activity, and collagen transmigration. J Bone Miner Res, 18, 1404–18
   PubMed Web of Science ®Google Scholar
• Yu JJ, Ruddy MJ, Wong GC, et al. (2007). An essential role for IL-17 in preventing pathogen-initiated bone destruction: Recruitment of neutrophils to inflamed bone requires IL-17 receptor-dependent signals. Blood, 109, 3794–802
   PubMed Web of Science ®Google Scholar
• Zhang Q, Guo R, Schwarz EM, et al. (2008). TNF inhibits production of stromal cell-derived factor 1 by bone stromal cells and increases osteoclast precursor mobilization from bone marrow to peripheral blood. Arthritis Res Ther, 10, R37
   PubMed Web of Science ®Google Scholar
• Zhang Y, Heulsmann A, Tondravi M, et al. (2001). Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem, 276, 563–8
   PubMedGoogle Scholar
• Zhang F, Tanaka H, Kawato T, et al. (2011). Interleukin-17A induces cathepsin K and MMP-9 expression in osteoclasts via celecoxib-blocked prostaglandin E2 in osteoblasts. Biochimie, 93, 296–305
   PubMed Web of Science ®Google Scholar
• Zhao B, Grimes SN, Li S, et al. (2012). TNF-induced osteoclastogenesis and inflammatory bone resorption are inhibited by transcription factor RBP-J. J Exp Med, 209, 319–34
   PubMed Web of Science ®Google Scholar
• Zhao B, Ivashkiv LB. (2011). Negative regulation of osteoclastogenesis and bone resorption by cytokines and transcriptional repressors. Arthritis Res Ther, 13, 234
   Google Scholar
• Zhao B, Takami M, Yamada A, et al. (2009). Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis. Nat Med, 15, 1066–71
   PubMed Web of Science ®Google Scholar
• Zheng H, Yu X, Collin-Osdoby P, Osdoby P. (2006). RANKL stimulates inducible nitric-oxide synthase expression and nitric oxide production in developing osteoclasts. An autocrine negative feedback mechanism triggered by RANKL-induced interferon-beta via NF-κB that restrains osteoclastogenesis and bone resorption. J Biol Chem, 281, 15809–20
   PubMed Web of Science ®Google Scholar
• Zheng T, Zhu Z, Liu W, et al. (2003). Cytokine regulation of IL-13Ralpha2 and IL-13Ralpha1 in vivo and in vitro. J Allergy Clin Immunol, 111, 720–8
   PubMed Web of Science ®Google Scholar
• Zhou P, Kitaura H, Teitelbaum SL, et al. (2006). SHIP1 negatively regulates proliferation of osteoclast precursors via Akt-dependent alterations in D-type cyclins and p27. J Immunol, 177, 8777–84
   PubMed Web of Science ®Google Scholar
• Zwerina J, Redlich K, Polzer K, et al. (2007). TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci USA, 104, 11742–7
   PubMed Web of Science ®Google Scholar